> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Brookings Questions FDA’s New Voucher Program
- URL: https://www.fdaweb.com/brookings-questions-fdas-new-voucher-program/
- Published: 2025-10-03T12:00:00.000Z
- Updated: 2026-09-14T15:23:22.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159987

A new Brookings Institution commentary is raising concerns about FDA’s new Commissioner’s National Priority Voucher (CNPV) pilot program, arguing that its core incentive of accelerated drug reviews may fall short of advancing broader public health goals like onshoring drug production and improving affordability. Launched in June, the CNPV program offers drugmakers the chance to earn a voucher for a 30–60 day review if they propose initiatives that advance one or more of five priorities: tackling public health crises, delivering innovative cures, addressing unmet needs, strengthening supply chains through U.S.-based manufacturing, and lowering costs.

Brookings analyst **Ryan Conrad** says that while faster reviews can boost profitability by bringing drugs to market earlier, the program’s design does little to compel companies to build new U.S. manufacturing facilities or cut prices. “A faster regulatory review will not lower production costs, offset the capital expenditure of building new facilities, nor will it compel a company to reduce its drug prices,” the [commentary](https://www.brookings.edu/articles/fdas-new-commissioners-national-priority-voucher-has-lofty-goals-can-it-deliver/?ref=fdaweb.com) contends.

It also points to structural misalignments in the program. One example is “undesignated vouchers,” which can be awarded for non-drug proposals like onshoring production, but later redeemed for drugs that had no direct link to the original pledge. Brookings warns that this risks turning domestic manufacturing promises into bargaining chips without enforceable follow-through.

Another concern raised is feasibility. Although FDA has advertised 30–60 day reviews, Brookings estimates the real timeline will be closer to 120–150 days when accounting for required pre-submissions, facility inspections, and possible extensions. That would mean the vouchers save only one or two months compared to existing six-month priority reviews — an acceleration analysts estimate is worth $35 to $70 million. That incentive, they argue, is too modest to drive major investments in onshoring or affordability.

Brookings recommends that FDA consider making vouchers transferable, especially for companies focused on generic sterile injectables, where domestic shortages are an ongoing crisis. It also calls for binding commitments and greater transparency to ensure that affordability and manufacturing promises are honored.

“The risk is not failure, but irrelevance,” the commentary concludes, warning that the pilot could end up accelerating only a handful of drugs without achieving its broader goals of strengthening supply chains and lowering costs.